iCAD announced new real-world research confirms ProFound AI has been proven to increase cancer detection rates and provide vital clues for breast imagers’ clinical decisions through two studies. One study demonstrated that ProFound AI improved radiologists’ performance in detecting breast cancer and providing better accuracy, without increasing abnormal interpretation rates or the rate of recalls. The second study highlighted that the lesion and Case Scores provided by ProFound AI offer important information about the algorithm’s confidence in identifying malignancy, with sequential changes in these scores offering significant additional insights. These studies were presented at the American Roentgen Ray Society meeting, which took place April 16-20 in Honolulu, HI. "The body of evidence supporting our Breast AI Suite grows as leading facilities and academic institutions worldwide continue to validate the unmatched results and benefits our technologies offer," said Dana Brown, President and CEO of iCAD, Inc. "The studies presented at the ARRS meeting confirm that ProFound AI not only improves radiologists’ performance and aids in the detection of breast cancer, but also reveals valuable clues over time through Case Scores, which can help clinicians make more informed clinical decisions and personalize patient care."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ICAD:
- iCAD appoints Lonnqvist as CFO, appoints new senior executives
- iCAD price target lowered to $4 from $7 at JMP Securities
- iCAD announces publication of clinical data for ProFound AI Risk
- ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments
- iCAD price target lowered to $2.50 from $5 at Lake Street
